<DOC>
	<DOCNO>NCT02437019</DOCNO>
	<brief_summary>The purpose study provide early access Ibrutinib treatment participant relapse refractory Chronic Lymphocytic Leukemia ( CLL ) collect additional safety data medication commercially available .</brief_summary>
	<brief_title>Early Access Program ( EAP ) Ibrutinib Participants With Relapsed Refractory Chronic Lymphocytic Leukemia ( CLL )</brief_title>
	<detailed_description>This open-label ( people know identity intervention ) , multi-center ( one hospital medical school team work medical research study ) early access program ( EAP ) study . The study conduct 2 phase : Screening Phase ( approximately 30 day prior administration first dose ) Program Drug Phase ( Day 1 30 Days last dose study drug ) . Enrolled participant receive 420 milligram ( mg ) oral ibrutinib daily 28-day cycle disease progression , occurrence unacceptable toxicity , long achieve clinical benefit , end program . Treatment continuous ( without interruption ) self-administered . Disease evaluation conduct accord local standard care clinically indicate . Participant 's safety monitor throughout study . All enrol on-going participant program continue receive ibrutinib EAP marketing approval 6 month date .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<criteria>Has Eastern Cooperative Oncology Group ( ECOG ) performance status less ( &lt; ) 2 Has diagnosis Chronic Lymphocytic Leukemia ( CLL ) meet publish diagnostic criterion ( Hallek 2008 ) : 1 . Monoclonal Bcells ( either kappa lambda light chain restrict ) clonally coexpressing least one Bcell marker ( Cluster Differentiation 19 [ CD19 ] , CD20 , CD23 ) CD5 2 . The diagnosis CLL require history lymphocytosis Blymphocyte count great equal ( &gt; = ) 5,000/microliter ( Î¼l ) Active disease meeting least one International Workshop Chronic Lymphocytic Leukemia ( IWCLL ) 2008 criterion Must receive least one prior therapy CLL appropriate treatment retreatment purine analog base therapy Able receive outpatient treatment laboratorial monitoring institution administers program drug Known central nervous system ( CNS ) lymphoma leukemia Known prolymphocytic leukemia history currently suspect Richter 's transformation Uncontrolled autoimmune hemolytic anemia ( AIHA ) idiopathic thrombocytopenic purpura ( ITP ) Prior exposure ibrutinib randomization ibrutinib study Requires treatment strong Cytochrome P3A4/5 ( , CYP3A4/5 ) Inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>PCI-32765</keyword>
	<keyword>Ibrutinib</keyword>
	<keyword>Early access program</keyword>
	<keyword>Chronic lymphocytic leukemia</keyword>
	<keyword>Relapsed refractory chronic lymphocytic leukemia</keyword>
</DOC>